Replies to post #14664 on BioSante Pharmaceuticals, Inc. (BPAX)

[Just the facts maam]

Alpha611, take a good look at both company pipelines.

Now look at their market caps. ACTC has a market cap of $162 M while Bpax has a market cap of $62 M.

ACTC has one drug approved for phase II trial the rest is in phase 1 or less.

BPAX has taken Elestrin and Bio-t-gel through FDA approval and are on the verge of an NDA submission for Libigel for one or more treatments. In addition their cancer portfolio consist of 17 phase 1 or 2 trials. The Pill Plus will also most likely be starting a phase III trial later this year.

Not hard to see which is the best value long term. Short term is always less predictable as you can see by the share price for Bpax over the last couple of months.